Advertisement


Bruce Minksy, MD's, Expert Perspective: Radiotherapy in 2015

2015 ASTRO Annual Meeting

Advertisement

ASTRO President Bruce Minsky, MD, of MD Anderson Cancer Center, talks about the goals and highlights of this year’s ASTRO Annual Meeting.



Related Videos

Gastroesophageal Cancer
Colorectal Cancer

Leonard Gunderson, MD, on the Presidential Symposium Lecture on Upper and Lower GI Cancers

Leonard Gunderson, MD, of the Mayo Clinic College of Medicine, discusses PET/CT imaging in upper and lower gastrointestinal cancers, which can be of value as a baseline study prior to treatment, in determining the degree of response to treatment, and in helping decide whether there is a relapse after a complete response to treatment.

Prostate Cancer

James B. Yu, MD, on RTOG 0415: Fractionation Schedules in Patients With Low-Risk Prostate Cancer

James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).

Head and Neck Cancer
Prostate Cancer

Bruce Minsky, MD, on Clinical Trial Results: The ASCENDE-RT Trial and a Multicenter Study on Prostate Cancer

Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).

Breast Cancer

Jay Harris, MD, on Making Sense of Conflicting Data on Breast Irradiation

Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses the difficulty reconciling recent important trials on radiotherapy for breast cancer: The Z11 trial suggested that breast tangents are sufficient, while MA.20 and EORTC studies suggested that full nodal irradiation is beneficial.

Prostate Cancer

Anthony Zietman, MD, on Hormonal Therapy and Salvage Radiation: Results of RTOG 9601

Anthony Zietman, MD, of Massachusetts General Hospital, discusses his perspective on the study of bicalutamide during and after radiotherapy in patients following radical prostatectomy and a biochemical relapse (Abstract LBA5).

Advertisement

Advertisement




Advertisement